Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alka Seltzer Extra Strength · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Arm 4 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Acetylsalicylic Acid (Aspirin BAY1019036) | DRUG | One tablet of new formula Aspirin under fasting conditions |
| Alka Seltzer Extra Strength | DRUG | One effervescent tablet under fasting conditions |
| Aspirin Migraine | DRUG | One effervescent tablet under fasting conditions |
| Aspirin Aspro | DRUG | One effervescent tablet under fasting conditions |
Inclusion Criteria: * Healthy male and female subjects between 18 to 55 years of age inclusive with a Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs) * Results of screening and clinical laboratory tests are within normal range or considered not clini...
Alka Seltzer Extra Strength is an effervescent aspirin product developed by Bayer AG. It is a small molecule formulation studied for pharmacokinetics, the way the body absorbs, distributes, and clears the drug. The product is associated with the Alka Seltzer brand, which is marketed by Bayer.
Alka Seltzer Extra Strength is made by Bayer AG, which trades over the counter in the United States under the ticker BAYRY. Bayer is the developer associated with this effervescent aspirin product.
Alka Seltzer Extra Strength has been studied in a Phase 1 clinical trial. The single registered trial is completed, so no active trials are ongoing. It is an investigational formulation in clinical development rather than a newly approved product.
Alka Seltzer Extra Strength has been evaluated in one completed Phase 1 trial, NCT01081353, titled Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin. The trial enrolled 26 healthy adult volunteers in the United States, was randomized and active controlled, and was not double blind.
Alka Seltzer Extra Strength is a small molecule effervescent aspirin formulation. Its pharmacokinetic profile was compared with that of plain aspirin in a Phase 1 study, meaning the trial measured how the body processes the drug rather than testing it against a disease.